BIOMAT Database Logo BIOMAT Database Logo

New Triazine Derivatives as Serotonin 5-HT6 Receptor Ligands. 2023

Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.

Since the number of people with Alzheimer's disease (AD) continues to rise, new and effective drugs are urgently needed to not only slow down the progression of the disease, but to stop or even prevent its development. Serotonin 5-HT6 receptor (5-HT6R) ligands are still a promising therapeutic target for the treatment of AD. 1,3,5-Triazine derivatives, as novel structures lacking an indole or a sulfone moiety, have proven to be potent ligands for this receptor. In present work, new derivatives of the compound MST4 (4-((2-isopropyl-5-methylphenoxy)methyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine), the potent 5-HT6R antagonist (Ki = 11 nM) with promising ADMET and in vivo properties, were designed. The synthesized compounds were tested for their affinity towards 5-HT6R and other receptor (off)targets (serotonin 5-HT2A, 5-HT7 and dopamine D2). Based on the new results, 4-(2-tert-butylphenoxy)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (3) was selected for extended in vitro studies as a potent and selective 5-HT6R ligand (Ki = 13 nM). Its ability to permeate the blood-brain barrier (BBB) and its hepatotoxicity were evaluated. In addition, X-ray crystallography and solubility studies were also performed. The results obtained confirm that 6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine derivatives, especially compound 3, are promising structures for further pharmacological studies as 5-HT6R ligands.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines

Related Publications

Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands.
April 2004, Bioorganic & medicinal chemistry letters,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
N-arylsulfonyl-2-vinyltryptamines as new 5-HT6 serotonin receptor ligands.
June 2006, Journal of enzyme inhibition and medicinal chemistry,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
Quinoline Derivatives as 5-HT6 Receptor PET Ligands.
April 2014, ACS medicinal chemistry letters,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
February 2010, Journal of medicinal chemistry,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
5-HT6 receptor ligands as antidementia drugs.
January 2011, International review of neurobiology,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment.
July 2019, International journal of molecular sciences,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands.
March 2005, Bioorganic & medicinal chemistry letters,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands.
November 2001, Journal of medicinal chemistry,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
[1,2,4]Triazole derivatives as 5-HT(1A) serotonin receptor ligands.
February 2002, Bioorganic & medicinal chemistry,
Dorota Łażewska, and Małgorzata Więcek, and Grzegorz Satała, and Paulina Chałupnik, and Ewa Żesławska, and Ewelina Honkisz-Orzechowska, and Monika Tarasek, and Gniewomir Latacz, and Wojciech Nitek, and Ewa Szymańska, and Jadwiga Handzlik
Pharmacokinetics of 5-HT6 receptor ligands.
January 2010, International review of neurobiology,
Copied contents to your clipboard!